종양학 기반 In-vivo CRO 시장 규모, 점유율, 동향 분석 리포트 : 적응증별, 지역별, 부문 예측(2024-2030년)

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.37 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 8.58% over the forecast period. An increase in outsourcing of R&D activities, high demand for advanced medicines, and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling pharmaceutical companies to seek the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs, which have been successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker, an analytical solutions company, acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

• The solid tumors segment held the largest share of 47.4% owing to the increasing incidence of cancer across the globe, and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
• Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 9.21% over the forecast period
• North America accounted for the largest global share of 49.97% in 2023, with the major contributions from the U.S., owing to increased funding available in the region. This has boosted research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
• Asia Pacific is anticipated to register the fastest CAGR over the forecast period, owing to many developed countries investing in Asia Pacific regions and the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
• 1.3. Regional Scope
• 1.4. Estimates And Forecast Timeline
• 1.5. Objectives
  • 1.5.1. Objective-1
  • 1.5.2. Objective-2
  • 1.5.3. Objective-3
• 1.6. Research Methodology
• 1.7. Information Procurement
  • 1.7.1. Purchased Database
  • 1.7.2. GVR's Internal Database
  • 1.7.3. Secondary Sources
  • 1.7.4. Primary Research
• 1.8. Information Or Data Analysis
  • 1.8.1. Data Analysis Models
• 1.9. Market Formulation & Validation
• 1.10. Model Details
  • 1.10.1. Commodity Flow Analysis
  • 1.10.2. Parent Market Analysis
• 1.11. List Of Secondary Sources
• 1.12. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Oncology Based In-vivo CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Accelerating the time to market
    • 3.2.1.2. Economic efficiency
    • 3.2.1.3. Increasing mergers and collaborations
    • 3.2.1.4. Increasing outsourcing of R&D Activities
  • 3.2.2. Market Restraint Analysis
• 3.3. Oncology Based In-vivo CRO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis
  • 3.3.4. Major Deals & Strategic Alliances Analysis

Chapter 4. Oncology Based In-vivo CRO Market: Indication Estimates & Trend Analysis

• 4.1. Oncology Based In-vivo CRO Market, By Indication: Segment Dashboard
• 4.2. Oncology Based In-vivo CRO Market, By Indication: Movement Analysis
• 4.3. Oncology Based In-vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
  • 4.3.1. Blood cancer
    • 4.3.1.1. Blood Cancer Market, 2018 to 2030 (USD Million)
    • 4.3.1.2. Syngeneic model
    • 4.3.1.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
    • 4.3.1.3. Patient-derived xenograft
    • 4.3.1.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.1.4. Xenograft
    • 4.3.1.4.1. Xenograft Market, 2018 to 2030 (USD Million)
  • 4.3.2. Solid tumor
    • 4.3.2.1. Solid Tumor Market, 2018 to 2030 (USD Million)
    • 4.3.2.2. Syngeneic model
    • 4.3.2.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
    • 4.3.2.3. Patient derived xenograft
    • 4.3.2.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.2.4. Xenograft
    • 4.3.2.4.1. Xenograft Market, 2018 to 2030 (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Others Market, 2018 to 2030 (USD Million)
    • 4.3.3.2. Syngeneic model
    • 4.3.3.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
    • 4.3.3.3. Patient derived xenograft
    • 4.3.3.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.3.4. Xenograft
    • 4.3.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)

Chapter 5. Oncology Based In-vivo CRO Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2023 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Global Regional Market Snapshot
• 5.4. North America
  • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Scenario
    • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Scenario
    • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Scenario
    • 5.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030
• 5.5. Europe
  • 5.5.1. UK
    • 5.5.1.1. Key Country Dynamics
    • 5.5.1.2. Competitive Scenario
    • 5.5.1.3. Regulatory Scenario
    • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 5.5.2. Germany
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Scenario
    • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 5.5.3. France
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Scenario
    • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 5.5.4. Italy
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Competitive Scenario
    • 5.5.4.3. Regulatory Scenario
    • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 5.5.5. Spain
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Competitive Scenario
    • 5.5.5.3. Regulatory Scenario
    • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 5.5.6. Denmark
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Competitive Scenario
    • 5.5.6.3. Regulatory Scenario
    • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 5.5.7. Sweden
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Competitive Scenario
    • 5.5.7.3. Regulatory Scenario
    • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 5.5.8. Norway
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Competitive Scenario
    • 5.5.8.3. Regulatory Scenario
    • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 5.6. Asia Pacific
  • 5.6.1. Japan
    • 5.6.1.1. Key Country Dynamics
    • 5.6.1.2. Competitive Scenario
    • 5.6.1.3. Regulatory Scenario
    • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 5.6.2. China
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Scenario
    • 5.6.2.4. China Market Estimates and Forecasts, 2018 - 2030
  • 5.6.3. India
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Scenario
    • 5.6.3.4. India Market Estimates and Forecasts, 2018 - 2030
  • 5.6.4. South Korea
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Competitive Scenario
    • 5.6.4.3. Regulatory Scenario
    • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 5.6.5. Australia
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Competitive Scenario
    • 5.6.5.3. Regulatory Scenario
    • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 5.6.6. Thailand
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Competitive Scenario
    • 5.6.6.3. Regulatory Scenario
    • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 5.7. Latin America
  • 5.7.1. Brazil
    • 5.7.1.1. Key Country Dynamics
    • 5.7.1.2. Competitive Scenario
    • 5.7.1.3. Regulatory Scenario
    • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 5.7.2. Argentina
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Competitive Scenario
    • 5.7.2.3. Regulatory Scenario
    • 5.7.2.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 5.8. MEA
  • 5.8.1. South Africa
    • 5.8.1.1. Key Country Dynamics
    • 5.8.1.2. Competitive Scenario
    • 5.8.1.3. Regulatory Scenario
    • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 5.8.2. Saudi Arabia
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Competitive Scenario
    • 5.8.2.3. Regulatory Scenario
    • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 5.8.3. UAE
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Competitive Scenario
    • 5.8.3.3. Regulatory Scenario
    • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 5.8.4. Kuwait
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Competitive Scenario
    • 5.8.4.3. Regulatory Scenario
    • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
  • 6.1.1. Innovators
  • 6.1.2. Market Leaders
  • 6.1.3. Emerging Players
  • 6.1.4. Company Market Share Analysis, 2023
• 6.2. Company Profiles
  • 6.2.1. Charles River Laboratory (CRL)
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Financial Performance
    • 6.2.1.3. Service Benchmarking
    • 6.2.1.4. Strategic Initiatives
  • 6.2.2. ICON Plc
    • 6.2.2.1. Company Overview
    • 6.2.2.2. Financial Performance
    • 6.2.2.3. Service Benchmarking
    • 6.2.2.4. Strategic Initiatives
  • 6.2.3. Thermo Fisher Scientific Inc.
    • 6.2.3.1. Company Overview
    • 6.2.3.2. Financial Performance
    • 6.2.3.3. Service Benchmarking
    • 6.2.3.4. Strategic Initiatives
  • 6.2.4. Eurofins Scientific
    • 6.2.4.1. Company Overview
    • 6.2.4.2. Financial Performance
    • 6.2.4.3. Service Benchmarking
    • 6.2.4.4. Strategic Initiatives
  • 6.2.5. Taconic Biosciences
    • 6.2.5.1. Company Overview
    • 6.2.5.2. Financial Performance
    • 6.2.5.3. Service Benchmarking
    • 6.2.5.4. Strategic Initiatives
  • 6.2.6. Crown Bioscience
    • 6.2.6.1. Company Overview
    • 6.2.6.2. Financial Performance
    • 6.2.6.3. Service Benchmarking
    • 6.2.6.4. Strategic Initiatives
  • 6.2.7. Lab Corp
    • 6.2.7.1. Company Overview
    • 6.2.7.2. Financial Performance
    • 6.2.7.3. Service Benchmarking
    • 6.2.7.4. Strategic Initiatives
  • 6.2.8. WuXi AppTec
    • 6.2.8.1. Company Overview
    • 6.2.8.2. Financial Performance
    • 6.2.8.3. Service Benchmarking
    • 6.2.8.4. Strategic Initiatives
  • 6.2.9. EVOTEC
    • 6.2.9.1. Company Overview
    • 6.2.9.2. Financial Performance
    • 6.2.9.3. Service Benchmarking
    • 6.2.9.4. Strategic Initiatives
  • 6.2.10. The Jackson Laboratory
    • 6.2.10.1. Company Overview
    • 6.2.10.2. Financial Performance
    • 6.2.10.3. Service Benchmarking
    • 6.2.10.4. Strategic Initiatives